SXC-2023

SXC-2023
Clinical data
Other namesSXC2023
Routes of
administration		Oral[1]
Drug classCystine–glutamate antiporter activator; Glutamate modulator
Identifiers
  • (2R)-2-acetamido-3-(4-methylbenzoyl)sulfanylpropanoic acid
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC13H15NO4S
Molar mass281.33 g·mol−1
3D model (JSmol)
  • CC1=CC=C(C=C1)C(=O)SC[C@@H](C(=O)O)NC(=O)C
  • InChI=1S/C13H15NO4S/c1-8-3-5-10(6-4-8)13(18)19-7-11(12(16)17)14-9(2)15/h3-6,11H,7H2,1-2H3,(H,14,15)(H,16,17)/t11-/m0/s1
  • Key:QHXPWGXGEBJOCG-NSHDSACASA-N

SXC-2023 is a cystine–glutamate antiporter (SLC7A11; System xc- or Sxc) activator or glutamate modulator which is under development for the treatment of impulse control disorders such as trichotillomania (hair-pulling disorder).[2][3][4][5][6] It is also being studied for treatment of cocaine-related disorders and smoking withdrawal.[2][3] The drug is taken orally.[1] The effects of SXC-2023 in animals have been studied.[4] SXC-2023 was first described in the scientific literature by 2018.[4] It was originated by Marquette University and the University of Wisconsin at Milwaukee and is under development by Promentis Pharmaceuticals and the National Institute on Drug Abuse (NIDA).[2][3] As of June 2025, the drug is in phase 2 clinical trials.[2][3]

See also

References

  1. ^ a b "Promentis starts dosing in trial of SXC-2023 for trichotillomania". Clinical Trials Arena. 18 January 2019. Retrieved 26 January 2026.
  2. ^ a b c d "SXC 2023". AdisInsight. 2 June 2025. Retrieved 26 January 2026.
  3. ^ a b c d "Delving into the Latest Updates on SXC-2023 with Synapse". Synapse. 8 May 2025. Retrieved 26 January 2026.
  4. ^ a b c Beyer C, Neary M, Lawton D, Baker D (2018). "SXC-2023: Characterization of a Novel Activator of the Cystine-Glutamate Antiporter and Potential Therapeutic for CNS Disorders". Neuropsychopharmacology. ACNP 57th Annual Meeting: Poster Session III: W72. 43 (S1): 383–527. doi:10.1038/s41386-018-0268-5. ISSN 0893-133X. Retrieved 26 January 2026.
  5. ^ Beyer CE, Neary MP, Lawton DG, Pentikis HS, Preigh MJ, Pimentel-Cotter P, et al. (September 2019). "SXC-2023: a small-molecule activator of the cystine–glutamate antiporter and potential therapeutic for central nervous system disorders is safe and welltolerated in phase I studies". Innovations in Clinical Neuroscience. CNS Summit: Selected Abstracts from the 2019 Meeting. 16 (9–10): S5–S19. PMC 7706851. PMID 33282525.
  6. ^ Hoffman J, Williams T, Rothbart R, Ipser JC, Fineberg N, Chamberlain SR, et al. (September 2021). "Pharmacotherapy for trichotillomania". The Cochrane Database of Systematic Reviews. 2021 (9) CD007662. doi:10.1002/14651858.CD007662.pub3. PMC 8478440. PMID 34582562.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.